Sorry people, I can answer my own question with the help of Google Gemini.
---
Company Actions to Mitigate or Remove Risk:
Addressing Non-Clinical Toxicity Studies: The primary action InhaleRx is taking is to complete the required non-clinical toxicology studies. The company expects to be able to lift the clinical hold upon completion of these studies, which will finalize the IRX-616a non-clinical testing program. This combined program is expected to be completed by the end of 2027.
---
IRX 616a World 1st Fast Acting Non Addictive Anxiety Solution, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.964M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 180072 | 3.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 330000 | 1 |
View Market Depth
| Last trade - 16.21pm 18/07/2025 (20 minute delay) ? |
| IRX (ASX) Chart |
Day chart unavailable